End-of-day quote
Mexican S.E.
06:00:00 2024-05-19 pm EDT
5-day change
1st Jan Change
17.06
MXN
+0.89%
-1.27%
+20.48%
Presentation Operator MessageOperator (Operator)Good morning, ladies and gentlemen. Thank you ...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2024 Earnings Call, Apr 25, 2024
Apr. 25
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 24
CI
Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend
Mar. 13
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q4 2023 Earnings Call, Feb 22, 2024
Feb. 22
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Feb. 21
CI
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 21
CI
Genomma Lab Internacional, S.A.B. De C.V. Announces Sixth Dividend Payment
Dec. 13
CI
Procaps Group and Genomma Lab Announce Strategic Agreement to Manufacture and Market Softgel Products in Latin America
Nov. 29
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q3 2023 Earnings Call, Oct 26, 2023
23-10-26
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
23-10-24
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q2 2023 Earnings Call, Jul 27, 2023
23-07-27
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-07-26
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2023 Earnings Call, Apr 27, 2023
23-04-27
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-27
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V. - Analyst/Investor Day
23-03-08
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q4 2022 Earnings Call, Feb 23, 2023
23-02-23
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
23-02-22
CI
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Full Year Ended December 31, 2022
23-02-22
CI
IFC and Genomma Lab Sign Multi-Currency Long-Term Loan to Boost Access to OTC Medicines in Latin America and the Caribbean Region
23-01-09
CI
Genomma Lab Internacional, S.A.B. de C.V. Announces CEO Changes
22-11-28
CI
Genomma Lab Internacional, S.A.B. de C.V. Announces Management Changes
22-11-28
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q3 2022 Earnings Call, Oct 27, 2022
22-10-27
Genomma Lab Internacional, S.A.B. De C.V. Cash Dividend
22-10-26
CI
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-10-26
CI
Tranche Update on Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B)'s Equity Buyback Plan announced on March 20, 2013.
22-10-25
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
More about the company
Last Close Price
17.06
MXN
Average target price
19.46
MXN
Spread / Average Target
+14.05%
Consensus
1st Jan change
Capi.
+20.48% 967M +34.35% 705B +30.88% 583B -3.49% 364B +20.15% 332B +6.19% 291B +14.70% 238B -3.72% 210B +9.94% 209B +9.21% 169B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1